

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
Telephone: (609) 252-6385
Fax: (609) 252-4526

RECEIVED
CENTRAL FAX CENTER
DEC 08 2004

FACSIMILE TRANSMISSION

To: Examiner Frank I. Choi
U.S.P.T.O.

Date: December 8, 2004

Fax No.: (703) 872-9306

cc:

From: Terence J. Bogie

Pages: 11 (including cover)

THIS FACSIMILE CONTAINS PRIVILEGED OR CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE ADDRESSEE(S). EXCEPT FOR DELIVERY TO THE INTENDED RECIPIENT, ANY DISSEMINATION OR COPYING OF THIS FACSIMILE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE NOTIFY US AND RETURN THE ORIGINAL TO US AT THE ABOVE ADDRESS.

Re: Response to Advisory Action of December 1, 2004

U.S.S.N.: 10/047,583

Our Reference: BP8935B CIP


Examiner Choi:

Thank you for all of the voice mail messages regarding the above-identified patent application. The claims have been amended to further clarify subject matter that the applicants believe meets the statutory requirements for allowance.

If you have any questions or this facsimile is illegible, please do not hesitate to contact me at the telephone number set forth above.

Thank you for your assistance in this matter.

Sincerely,



Terence Bogie
Attorney for the Applicants

CASE BP8935B CIP

CERTIFICATE OF TRANSMISSION (37 CFR 1.8a)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (703) 872-9306 on December 8, 2004.

Terence J. Bojic
Type or print name

Terence J. Bojic
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Boulos et al.

ART UNIT: 1616

EXAMINER: Frank I. Choi

RECEIVED
CENTRAL FAX CENTER

DEC 08 2004

APPLICATION NO: 10/047,583

FILED: January 14, 2002

FOR: VITAMIN FORMULATION FOR CARDIOVASCULAR HEALTH

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is an amendment in the above-identified application.


Fee calculation:

Multiple Dependent Claims (\$ 300)						\$
For	Number Presented	Number Prev. Paid	Number Extra		Rate	
TOTAL CLAIMS	12	20	= 0	x \$ 18	=	\$ 0
INDEPENDENT CLAIMS	1	3	= 0	x \$ 88	=	\$ 0
TOTAL FEE						\$ 0

U.S.S.N: 10/047,583
Transmittal Letter

- No additional fee is required. The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. §1.16 and §1.17, which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.
- Enclosed is a Petition for Extension of Time.

Respectfully submitted,



Terence J. Bogie
Attorney for Applicants
Registration No. 44,544
Telephone No. (609) 252-6385
Facsimile No. (609) 252-4526

Date: December 8, 2004

Please forward all future correspondence relating to this application to:

Stephen B. Davis
Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

CASE BP8935B CIP

CERTIFICATE OF TRANSMISSION (37 CFR 1.8)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (703) 872-9306 on December 8, 2004.

Terence J. Bogie
Type or print name

Terence J. Bogie
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Boulos et al.

ART UNIT: 1616

EXAMINER: Frank I. Choi

APPLICATION NO: 10/047,583

FILED: January 14, 2002

FOR: VITAMIN FORMULATION FOR CARDIOVASCULAR HEALTH

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

RESPONSE TO ADVISORY ACTION

Applicants respectfully request a one-month extension of time. Enclosed herewith is a Petition for Extension of Time pursuant to 37 CFR §1.136(a).

Applicants filed a Notice of Appeal in the above-identified application on October 12, 2004. An Advisory Action was issued in the above-identified application on December 1, 2004. Applicants respectfully request that the above-identified patent application be amended, without prejudice, as follows:

Amendments to the Claims are reflected in the amendments in the listing of claims, which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.